Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. To validate our optimized parameter sets, we simulated 100 trials, each with 30 subjects in five treatment arms. Forward-Looking Statements Statements herein relating to future business performance, conditions or strategies and other financial and business matters, including expectations regarding clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. In the field of antibacterials, AiCuris seeks to develop innovative treatment options for life-threatening, (multidrug)-resistant hospital-treated pathogens. 23.06.2016 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. In immunocompromised patients, HSV can lead to serious complications.
28, 2016 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. In addition, it does not require activation within an HSV infected cell by viral thymidine kinase and is therefore also protective to uninfected cells. Currently the company is running two clinical development programs with pritelivir. Strüngmann. A webcast replay of the conference call will be available on the Genocea website beginning approximately two hours after the event, and will be archived for 30 days. The peer-reviewed JAMA article reports the results of a second clinical phase 2 study to compare the efficacy of pritelivir with valacyclovir for suppression of HSV-2 infections. Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228) Lischka P, Michel D, Zimmermann H.
In a further secondary analysis measuring the impact on genital lesion rates, GEN-003 demonstrated sustained and statistically significant reductions from baseline in five of six dose groups ranging from 43 to 69 percent. The pneumococcus and herpes vaccines are Genocea’s only programs in clinical trials. Clark presented data demonstrating the Company’s belief that GEN-003 could have upwards of $2 billion global revenue potential if successfully developed worldwide. Following this, Genocea plans to study the interaction of GEN-003 with oral antivirals for herpes. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. All subjects will be followed for 12 months after the last dose. GEN-003 led to a 48 percent reduction in viral shedding and a 52 percent reduction in lesions in its previous, Phase 1/2 trial.
About Genocea Biosciences Inc. However, intelligent or not, I fear that these individuals may be selling out their integrity to support a flavor-of-the-day herpes vaccine (i.e., the HerpV vaccine) that the objective measurements indicate is in the process of sinking, much like the Titanic after it hit that iceberg in the North Atlantic. The two independent vaccine programs – for herpes simplex virus (HSV) and cytomegalovirus (CMV) – have not entered clinical trials. Dr. The study was funded by Genocea Biosciences, the Cambridge, Mass.-based company that makes the drug. “In my experience, genital herpes is unique among sexually transmitted disease, in terms of its physical and emotional impact on patients, who experience significant fear upon receiving the diagnosis, as well as isolation during their lifelong struggle with the disease,” Nicholas Van Wagoner, MD, PhD, assistant professor of medicine in the Division of Infectious Diseases at the University of Alabama, said in a news release. Those dollars have come from a big-name investor pool that includes Polaris Partners (16.3 percent stake), Lux Ventures (14.8 percent), SR One, the venture arm of GlaxoSmithKline (13 percent), Johnson & Johnson Development Corp.
Note that most groups also saw a significant reduction in lesions, and between 16% and 32% were recurrence-free 12 months after vaccination. If, at any time, you are interested in reverting to our default settings, please select Default Setting above. We have advanced our lead candidate, GEN-003, a novel T cell-enabled immunotherapy for genital herpes, into Phase 2 clinical development, while also exploring earlier-stage candidates in immuno-oncology. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. In addition, material that is unduly hostile, threatening, illegal or similarly unsuitable will be excluded, with the provision that any communication that is filtered out must be made available to any non-management director upon request. There is no licensed vaccine to prevent malaria, an infection caused by Plasmodium parasites transmitted by mosquitoes. uses its discovery platform called AnTigen Lead Acquisition System (ATLAS™) to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses, in contrast to approved vaccines and immunotherapies, which are designed to act mainly through B cell (or antibody) immune responses.
The company will also provide a business update, including details on independent and partnered development programs in the conference call and webcast. We manufactured the vaccine and the adjuvant under a $1.3 million contract, and provided regulatory and clinical expertise. Step 1: Have a look at our weekly job list containing the latest and coolest job and internship offers in the field!